{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.7","value":"80.7"},{"groupId":"OG001","spread":"21.6","value":"72.5"},{"groupId":"OG002","spread":"15.5","value":"73.6"},{"groupId":"OG003","spread":"15.6","value":"71.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"20"}],"units":"Participants"}],"title":"At baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.6","value":"75.6"},{"groupId":"OG001","spread":"16.9","value":"76.3"},{"groupId":"OG002","spread":"17.5","value":"73.6"},{"groupId":"OG003","spread":"11.9","value":"74.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"17"}],"units":"Participants"}],"title":"At week 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.8","value":"75.8"},{"groupId":"OG001","spread":"17","value":"77.4"},{"groupId":"OG002","spread":"12.2","value":"80"},{"groupId":"OG003","spread":"15.5","value":"72.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"16"}],"units":"Participants"}],"title":"At week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16","value":"75.2"},{"groupId":"OG001","spread":"15.5","value":"73"},{"groupId":"OG002","spread":"13.5","value":"77.9"},{"groupId":"OG003","spread":"11.7","value":"77.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"17"}],"units":"Participants"}],"title":"At week 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.2","value":"76"},{"groupId":"OG001","spread":"16.7","value":"73.4"},{"groupId":"OG002","spread":"16.4","value":"84"},{"groupId":"OG003","spread":"15.3","value":"73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"15"}],"units":"Participants"}],"title":"At week 26"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.6","value":"78.7"},{"groupId":"OG001","spread":"19.7","value":"68.9"},{"groupId":"OG002","spread":"15.6","value":"81.5"},{"groupId":"OG003","spread":"12.9","value":"73.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"13"}],"units":"Participants"}],"title":"At week 34"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.3","value":"80.1"},{"groupId":"OG001","spread":"21.8","value":"69"},{"groupId":"OG002","spread":"15.5","value":"77.3"},{"groupId":"OG003","spread":"15.3","value":"75.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"title":"At week 42"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.6","value":"78"},{"groupId":"OG001","spread":"15.3","value":"77.4"},{"groupId":"OG002","spread":"21","value":"78.8"},{"groupId":"OG003","spread":"13.5","value":"71.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"11"}],"units":"Participants"}],"title":"At week 50"}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"20"}],"units":"Participants"}],"description":"Euro-Quality of Life (EuroQoL) 5 dimension 5 level (EQ-5D-5L) questionnaire, comprising of 5 questions with a score from 1 (no problem) to 5 (extreme problem) and a visual analog scale from 0 (worst) to 100 (best).","dispersionType":"Standard Deviation","groups":[{"description":"Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab","id":"OG000","title":"Experimental Arm for Chemo Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance"},{"description":"Standard Chemotherapy for 4 to 6 cycles, followed by Observation","id":"OG001","title":"Control Arm for Chemo Cohort: Chemotherapy, Then Observation"},{"description":"Durvalumab + Standard Chemotherapy for 4 to 6 cycles, followed by Maintenance with Durvalumab","id":"OG002","title":"Experimental Arm for IO Cohort: Durvalumab + Chemotherapy, Then Durvalumab Maintenance"},{"description":"Ipilimumab every 6 weeks and Nivolumab every 2 or 3 weeks for up to 2 years.","id":"OG003","title":"Control Arm for IO Cohort: Ipilimumab and Nivolumab"}],"paramType":"MEAN","populationDescription":"The number analyzed for each row reflects the number of participants who completed the question at the corresponding time point.","reportingStatus":"POSTED","timeFrame":"Performed at baseline, then at weeks 6, 12, 18, 26, 34, 42, 50, then every 12 weeks and at first progression visit until disease progression (minimum follow-up is 24 months after randomisation).","title":"Health-Related QOL: EQ-5D-5L","type":"SECONDARY","unitOfMeasure":"score on a scale"}